curevac.com (CVAC) Company Gross Revenue

CureVac N.V. (CVAC) utilizes AI platforms and robotics to accelerate the synthesis of mRNA drugs. The company's product sales volumes demonstrate revenue dynamics, where the latest value is recorded as 0.08. Complex RNA delivery systems create a high barrier to entry, while current capital expenditures in laboratories and clinical trials are temporarily constraining the overall profitability of the business.

Company Sales: CureVac Corp (CVAC) for 07/04/2022 - 01/17/2026

Comprehensive metric breakdowns and analytics for CureVac (CVAC)

- price and consensus price forecast:

Stock Price CureVac Pharma|CVAC - Price Target Chart

- market capitalization details:

Market Capitalization CureVac N.V.|CVAC - Enterprise Value

- book capitalization data:

Accounting Value per Share CureVac|CVAC - Company Net Assets|Market Capitalization to Book Value Ratio curevac.com|CVAC - Aggregate Company Assets

- debt and solvency information:

- company profitability and valuation multiples indicators:

CVAC - Net Income|Expected Net Income CureVac N.V.|CVAC - Price to Earnings Ratio|Price to Future Earnings Ratio curevac.com|CVAC - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio CureVac N.V.|CVAC - Operating profit before deduction of amortization|Earnings per share for the last twelve months CureVac|CVAC - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months curevac.com|CVAC - Earnings growth in current year|Expected earnings per share growth for next year CureVac N.V.

- issuer revenue and sales details:

CVAC - Company Sales|Company Projected Revenue CureVac Pharma|CVAC - P/S Multiple|Forward P/S Multiple CureVac N.V.

General company analysis:CureVac Pharma

CureVac N.V. (CVAC) sales reflect the daily extent to which commercial plans are realized relative to market expectations. By analyzing the dynamics of the company's product sales, an investor determines the pace of market share capture. This metric measures actual cash inflow from sales, revealing the effectiveness of the monetization strategy. For CureVac N.V. (CVAC), this indicator confirms the return on the automation of mRNA vaccine synthesis. Robotic bioreactors accelerate drug production, directly impacting final revenue.

Key competitors